Thank you for Subscribing to Cannabis Business Insights Weekly Brief
Gerard Coombs Jr., CEOThe 2018 Farm Bill unleashed a wave of excitement across the hemp and cannabinoid space, sparking a rush of startups chasing quick wins.
“While many pursued fleeting trends, at Arvida Labs, we charted a different course. By committing to innovation and scientific rigor, we’ve grown from a small experiment into a leading name in cannabinoid production,” says Gerard Coombs Jr., CEO.
The Spark: A Scholar with an Entrepreneurial Spirit
Guiding Arvida Labs’ growth is Coombs, a pharmacy scholar turned entrepreneur. From advancing Delta-8 THC production to building an integrated supply chain, he combines scientific expertise with a strategic business approach.
In 2015, Coombs moved from Florida to Colorado on a scholarship to pursue a doctorate in pharmacy. Growing up, he had always been fascinated by the cannabis industry. But it was when he got to Colorado that his passion ignited. While attending grad school, he nurtured his entrepreneurial spirit by running a small online business. It was just to make a little extra income, but it planted the seeds of something much bigger.
With the money he saved, Coombs began buying lab equipment and experimenting with cannabis extracts. After finishing grad school, he immersed himself in the cannabis industry, attending networking events and selling vaporizer hardware and packaging to dispensaries. That’s when he met his two future business partners. Together, they developed an innovative automation technology for filling vaporizers with cannabis oils, something that had traditionally been costly and inefficient. Soon, they started building and selling vape-filling machines. While competitors relied on machines priced at $20,000, Arvida Labs engineered theirs to sell for just $500. At one point, its compact facility housed 15 machines, each operated by a single person, showcasing production efficiency far beyond most early-stage competitors.
Cracking the Code on Cannabinoid Synthesis
By 2018, a new cannabinoid was making waves; Delta-8 THC. Intrigued, Coombs and one of his partners, a PhD chemist from MIT, decided to experiment. Using the equipment in Coombs’ lab, they completed their first isomerization of Delta-8 within 24 hours. When Coombs contacted a customer with the final product, he was immediately offered a price nearly 10 times the production cost for that batch.
In this space, intellectual property isn’t just about formulations; it’s about owning the entire process from seed to shelf
Not long after, they introduced Mellow Fellow, a consumer-facing brand known for its quality and consistency. Creative direction for the brand was led by Lindsey Goldstein, Coombs’ sister-in-law and CMO at Arvida Labs. To solve the persistent supply chain challenges in the cannabinoid space, they founded Alpha Brands Distribution, bringing logistics and delivery under their control.
Today, these businesses operate together under the Arvida Group umbrella. In 2024, Arvida Labs took its final step toward full vertical integration by entering CBD extraction and hemp cultivation.
For Coombs, the strategy is clear. “In this space, intellectual property isn’t just about formulations; it’s about owning the entire process from seed to shelf.”
This philosophy is the foundation of Arvida Labs’ meteoric rise and the reason it’s at the forefront of the cannabinoid industry.
-
While many pursued fleeting trends, at Arvida Labs, we charted a different course. By committing to innovation and scientific rigor, we’ve grown from a small experiment into a leading name in cannabinoid production
Full-Spectrum Excellence: Arvida’s Edge in Cannabinoids
Arvida Labs’ success stems from its obsessive attention to detail. From the outset, the team has refined its methods to enhance efficiency, potency and product purity. By collaborating with analytical labs, they identified byproducts and optimized cannabinoid synthesis, a process still evolving across the industry.
Initially, Arvida Labs met the market’s call for high-potency products. But as the industry matured, so did its approach. With advanced analytical tools and deeper insight into cannabinoid chemistry, it shifted from hitting potency targets to delivering full-spectrum transparency. Today, Arvida Labs provides precise, high-purity formulations backed by detailed cannabinoid profiles.
Supporting this scientific rigor are chain-of-custody tracking and advanced analytics to ensure quality at every stage. A key partnership with High Standard, a premium vape hardware provider, allows Arvida Labs to align top-tier technology with each custom formulation.
Its vital differentiator lies in its fully integrated operations, spanning cultivation, extraction, manufacturing, co-packing, and distribution. This end-to-end control ensures consistency and efficiency across its offerings.
Client engagement is equally hands-on. It dedicates time to fully understanding brand identity, target audience, and go-to-market strategy. Using regional data, it tailors terpene profiles to local preferences, helping brands resonate with their specific markets.
In a fast-evolving landscape, Arvida Labs goes beyond production. Whether guiding regulatory adaptation or improving product flavor and effects, Coombs and his team serve as strategic partners, not just service providers.
Science-Driven Advocacy: Protecting Access, Empowering Entrepreneurs
With rapid industry changes, regulatory engagement is always essential. Coombs became actively involved in lobbying efforts, joining organizations like the American Health Alternatives Association (AHAA), where he now serves on the board, and the Florida Healthy Alternative Association. These roles have offered him a front-row seat to the complexities of policymaking and deepened his commitment to science-informed advocacy.
-4.jpg)
As someone with a Doctor of Pharmacy degree, Coombs brings a unique, evidence-based voice to the table, one that resonates with legislators whose primary concern is public safety, especially protecting children. His background enables him to translate the technical language of cannabinoid science into concepts regulators can understand and support.One powerful analogy he often uses is vitamin C. While people typically associate it with oranges, the vast majority of vitamin C sold in pharmacies is synthesized, chemically identical to the natural compound, yet more scalable and cost-effective. Synthesized cannabinoids follow the same principle, offering consistent, high-quality products that are both accessible and safe. Drawing these parallels helps demystify the science and demonstrate the legitimacy of synthesized compounds in the wellness space.
Beyond explaining the science, Coombs sees advocacy as a way to serve the broader community, particularly independent entrepreneurs. Due to heavy regulation, well-funded corporations often dominate the cannabis industry. But there is still room in the hemp and cannabinoid space for smaller players to grow. Through ongoing engagement with policymakers, Arvida Labs advocates for fair, balanced regulations that keep the industry open and competitive.
This advocacy isn’t driven by large corporate donors. It’s powered by grassroots support, by the same small business owners, local retailers, and emerging brands that make up the fabric of the industry.
“What I find most fulfilling is making sure these voices are represented—giving small businesses a real opportunity to succeed in a landscape that’s becoming more complex and regulated,” says Coombs.
From Molecules to Market Movers: A Blueprint for Industry Domination
Arvida Labs is making bold strides in the evolving cannabinoid industry. A key initiative is contract farming, which allows it to control its raw materials, ensuring greater product consistency and quality. Hands-on cultivation management strengthens its supply chain, reducing dependency on third-party growers and maintaining strict quality standards.
Building on this foundation of quality control, Arvida Labs is pioneering advancements in encapsulation technology to enhance bioavailability and product stability as hemp-derived beverages gain popularity. These innovations make cannabinoids more effective and accessible, setting new benchmarks in consumer wellness.
With deep expertise in extraction, formulation, and manufacturing, Arvida Labs is now expanding into cannabis production. As legalization expands across global markets, the company is leveraging its scientific and operational strengths to lead this next industry evolution.
On a global scale, Arvida Labs is expanding its operations and bringing its products, technology and industry knowledge to new markets. As the regulatory landscape continues to shift, Coombs envisions a future where hemp, cannabinoids and cannabis converge into a unified industry. With potential federal legalization on the horizon, Arvida Labs strategically positions itself as the premier supplier for major corporations entering the space.
Most consumers only know CBD and THC, but dozens of cannabinoids exist, each with unique properties and benefits. Arvida Labs is at the forefront of researching and producing compounds like Delta-8, Delta-10, iso-THC, and Delta-4, 8 THC.
With his pharmacy expertise, Coombs is passionate about exploring the pharmacological properties of cannabinoids and the ongoing research into their potential applications in supporting wellness—including areas such as discomfort, nausea, appetite regulation, and chronic conditions often experienced by patients undergoing cancer treatment From a small home lab to a vertically integrated powerhouse, Arvida Labs has built its success on scientific mastery, thoughtful strategy, and a commitment to pushing the industry forward.
Cannabinoid Manufacturing Under Strain From Split Supply Chains
Cannabinoid production rarely breaks in a visible way. It slips through timing gaps between synthesis, testing queues and packaging windows. A batch can pass chemistry inside the lab and still stall later because verification results return after production schedules have already moved on. That lag is where cost tends to accumulate, not in the reaction itself.
State-level regulatory differences shape production decisions more than most operators admit. A formulation that clears documentation in one jurisdiction may require additional testing or labeling adjustments in another. That forces manufacturers to keep recalibrating internal standards instead of relying on a single repeatable rule set across markets.
Equipment choices reflect how closely cannabinoid manufacturing now mirrors pharmaceutical environments. Reactor systems, filtration units and filling lines are often adapted from pharma-grade setups to keep variability contained during scale-up. The point is less about sophistication and more about avoiding drift between early pilot batches and high-volume runs.
Downstream pressure builds when products move into formats like vapes, edibles or blended cannabinoid oils. Retail partners rarely interpret technical differences in cannabinoids with consistency, which pushes manufacturers to carry part of that explanation into distribution. That added layer affects how inventory is staged and how quickly products can be released after testing clears.
Testing complexity has increased as cannabinoid isomers multiply. Small structural shifts can produce materially different results under chromatography, which means verification is not just a pass or fail step but a timing constraint. Labs working through queues often become the slowest point in the chain, even when production itself is stable.
Internal consolidation changes how these delays are managed. When formulation, synthesis and packaging sit under the same operational umbrella, fewer handoffs interrupt batch flow. Data from production runs, lab results and formulation adjustments stays closer to the point where decisions are made, which reduces dependence on external scheduling cycles.
Policy involvement has become part of operational planning rather than an external concern. Manufacturers that participate in regulatory discussions tend to translate technical constraints into language that fits legislative review. That exchange reduces uncertainty when production plans depend on shifting compliance interpretations across states.
Market conditions have moved cannabinoid production away from opportunistic extraction toward controlled throughput planning. Early-stage variability has been replaced by tighter expectations around repeatable reaction conditions and predictable batch timing. The pressure now sits on consistency rather than experimentation.
Differences between testing facilities can still produce uneven interpretations of the same material. Calibration standards help reduce disagreement, but maintaining alignment requires ongoing adjustment across instruments and protocols. That variability continues to influence contract negotiations between suppliers and brand operators.
Arvida Labs operates across cannabinoid synthesis, formulation support and downstream preparation rather than limiting itself to a single stage of production. It links laboratory conversion work with filling and distribution functions that usually sit across separate vendors. That structure reduces friction where batch timing, testing clearance and packaging schedules often collide. For cannabinoid manufacturers managing multi-state compliance and uneven lab turnaround times, this integrated setup provides a more direct production path without relying on fragmented external coordination. The result is tighter control over how inputs move from reaction stage to finished product release.
...Read more
